Metastatic Pancreatic CancerPhase 1REACtiVe-2NCT05650918
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
A Phase 1 study testing MesoPher and Mitazalimab in people with Metastatic Pancreatic Cancer, run by Joachim Aerts, MD PhD at 1 site in Netherlands.
Trial summary
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Pancreatic Cancer
- What is being tested?
- MesoPher and Mitazalimab
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteNetherlands
- Study dates
- 30 Aug 2021to 23 May 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Metastatic pancreatic cancer as defined by the presence of radiologically suspect metastatic lesions.
- Inclusion ≤ 4 weeks after stopping FOLFIRINOX chemotherapy.
- No more than 1 line of chemotherapy for metastatic disease is allowed. Prior FOLFIRINOX for locally advanced disease if given within 1 year before screening will be counted as first-line treatment. Any FOLFIRINOX given in the curative intent setting if more than a year before screening will not be considered first line therapy.
- An accessible metastatic lesion for histological tissue collection.
- Patients must be at least 18 years old and must be able to give written informed consent.
- WHO performance status 0-1.
Show all 13Show fewer
- Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count > 1.0 x 109/l, platelet count > 100 x 109/l, and Hb > 6.0 mmol/l (as determined during screening). Transfusion in the 2 weeks preceding screening is not allowed.
- Laboratory tests: ASAT/ALAT <5xULN (upper limit of normal), bilirubine <1.5xULN, Creatinine value <1.5xULN, Lactate dehydrogenase value < ULN and albumin value > LLN (lower limit of normal).
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on Day 1, and must be willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) or true abstinence (when this is in line with the preferred and usual lifestyle)* during the study and for at least 12 months after the last study drug administration.
- True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (such as calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- Men must be willing to use an effective contraceptive method (e.g. condom, vasectomy) during the study and for at least 12 months after the last study drug administration.
- Ability to return to the hospital for adequate follow-up as required by this protocol.
- Written informed consent according to ICH-GCP.
Who cannot join
- Medical or psychological impediment to probable compliance with the protocol.
- Abdominal ascites.
- Current or previous use of a CD40 antibody and/or anti-tumor vaccinations.
- Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has undergone curative intent treatment and has been disease-free for two years.
- Serious concomitant disease, or active infections.
Show all 13Show fewer
- History of autoimmune disease, organ allografts or active acute or chronic infection, including but not limited to HIV and viral hepatitis.
- Serious intercurrent chronic or acute illness such as pulmonary disease (asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for the investigational treatment.
- Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH)).
- Pregnant or lactating women.
- Inadequate vein access to perform leukapheresis.
- Concomitant participation in another clinical intervention trial (except participation in a biobank study).
- An organic brain syndrome or other significant psychiatric abnormality which would compromise the ability to give informed consent, and preclude participation in the full protocol and follow-up.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dendritic Cells Loaded With Allogeneic Tumor Lysate (MesoPher) in Combination With a CD40 Agonist (Mitazalimab) in Metastatic Pancreatic Disease
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.
Read the detailed description
Rationale: Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.
Objective: To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic cancer after standard-of-care (SOC) treatment with (modified) FOLFIRINOX.
Study design: Open-label, single-center, phase I dose finding study using a modified toxicity probability interval (mTPI) design.
Study population: Adults with metastatic pancreatic cancer after SOC treatment with (modified) FOLFIRINOX.
Intervention: Leukapheresis is performed after which monocytes are used for differentiation to dendritic cells. Autologous dendritic cells pulsed with an allogeneic tumor lysate (MesoPher) will be administered intra-dermally and intravenously 3 times every 2 weeks. Booster vaccinations are given after 3 and 6 months. On the same day after administration of MesoPher a CD40 agonist (mitazalimab) will be administered intravenously.
Study parameters/endpoints: The main study endpoint are the dose-limiting toxicities of MesoPher/mitazalimab combination therapy. The secondary endpoints are the induced immune responses on therapy and the radiographical response rate according to RECIST and iRECIST.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients have to undergo additional outpatient clinic visits for this study and additional invasive procedures specifically for this trial, e.g. intravenous catheter placement and tumor metastasis biopsies. Although these are invasive procedures, associated risks are limited. Intravenous access is necessary during every visit, i.e. for leukapheresis, for drawing blood samples and for the administration of study medication. Leukapheresis is a standard procedure and will be performed according to our institutional guidelines. Leukapheresis demonstrates a limited risk for transient thrombocytopenia and leukopenia. Previous clinical studies have shown that injection with tumor lysate-pulsed dendritic cells (MesoPher) was well tolerated without major systemic toxicity, with the exception of low-grade flu-like symptoms (REACtiVE Trial, NL67169.000.18; DENIM/MM04: NCT03610360; MM03 NL44330.000.14 / NCT02395679).
Also, intravenous injection of mitazalimab up to 1200 µg/kg was well tolerated with manageable side effects. There are currently no trials investigating this combination therapy. Combining two immunomodulatory drugs increases the risk for toxicity. The objective of this phase I study is to investigate safety and tolerability of administrating MesoPher/mitazalimab combination therapy in metastatic pancreatic cancer patients. Patients may have potential beneficial anti-tumor responses following study medication.
- Conditions
- Metastatic Pancreatic Cancer
- Being tested
- MesoPher, Mitazalimab
- Keywords
- Immunotherapy, CD40 agonist, Dendritic cell therapy
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MesoPherBiological
autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
MitazalimabBiological
agonistic human monoclonal (IgG1) antibody targeting CD40
| Study group | Role | What they receive |
|---|---|---|
| MesoPher and mitazalimab combination therapy | Experimental | MesoPher. 25 million lysate loaded DCs administered in the form of 3 biweekly and 2 additional vaccinations (3 and 6 months after the third vaccination). 1/3 intradermal injection in the forearm and 2/3 via the intravenous route.
mitazalimab, 75µg/kg-150µg/kg-300µg/kg-600µg/kg or 1200µg/kg via intravenous route in the form of 3 biweekly and 2 additional infusions (3 and 6 months after the third vaccination). Receives: Biological: MesoPher; Biological: Mitazalimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0
The number of patients experiencing a DLT will be determined. Toxicities will be scored according to CTC criteria version 5.0 (Published November 27th, 2017). The toxicities occurring during 6 weeks after the first vaccination (i.e., the DLT observation period), will be considered as DLT, when considered possibly, probably or definitively related to MesoPher and/or mitazalimab combination therapy. All patients that cannot complete the first 3 doses as planned due to directly related toxicity will be discussed in the Study Steering Committee and they will determine whether the patient is classified as having a DLT.
Measured: From first dose (week 0 of treatment phase) to end of the DLT observation period (week 6 of treatment phase)
Secondary outcomes (5)
Determine the presence of vaccine-induced dendritic cell mediated immune responses using ELISA and flow cytometry.
Keyhole Limpet Hemocyanin (KLH) responses: KLH is part of the DC vaccine and is used as a surrogate marker for DC-mediated immune stimulation and persistence of this response. KLH is known to induce a specific adaptive immune response readily detectable in sera (antibody response) and PBMC of vaccinated individuals. Serum samples will be collected before, during and after DC therapy as well as at selected intervals during follow-up. Humoral responses to KLH will be detected using ELISA. In addition, we will also measure cellular responses against KLH. Dendritic cells will be loaded with KLH protein lysate and co-cultured in vitro with PBMCs taken before and after study therapy. After co-culture, T cells will be stained for activation, cytotoxic and degranulation markers and measured by flow cytometry.
Measured: From baseline to end of study (week 36)
Determine the intratumoral treatment effect by measuring T cell influx
We will use immunohistochemistry to stain T cells in order to determine T cell influx before and after 3 study treatments.
Measured: From baseline to week 6
Determine vaccine-induced changes in the frequency of immune cell subsets using flow cytometry
Phenotypical analysis of peripheral blood mononuclear cells (PBMCs) will be conducted with Aurora spectral flow cytometry immune panels comprising 40 different antibodies to analyze changes in the lymphoid and myeloid cell compartments. Vaccine-induced changes in the frequencies of immune cell (subsets) that represent distinct lineages and/or express different levels of activation, differentiation and co-signaling markers are measured. Combination of these readouts allows for the generation of immune profiles for individual patients.
Measured: From baseline to end of study (week 36)
Determining predictive gene expression signatures related to therapy outcome using NanoString technology
Immuno-oncology gene expression signatures will be determined on PBMCs obtained pre- and post-combination treatment and on RNA isolated from OCT-embedded positive DTH skin reactions. This provides us with comprehensive profiling of the immune response including mechanistic pathway activity induced by DC/αCD40 combination therapy.
Measured: From baseline to end of study (week 36)
Radiological response rate as defined by RECIST version 1.1 and iRECIST
Patients undergo regular radiological evaluations until documented evidence of progression as defined by RECIST 1.1 criteria. After each radiographic evaluation patients will be assigned a RECIST response of complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) depending on the status of their disease compared to baseline and previous assessments. If a patient has had a radiological assessment, which cannot be evaluated, then the patient will be assigned a visit response of not evaluable (NE) (unless there is evidence of progression, in which case the response will be assigned as PD).
Measured: From baseline to end of study (week 36)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2022
- Study start30 Aug 2021
- Primary completion23 May 2023
- Study completion23 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Sequential
- Model description
- open-label, dose-finding, single-center phase I study
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Joachim Aerts, MD PhD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Joachim Aerts, MD PhD, Erasmus Medical Center
- Investigators
- Ferry Eskens, MD, PhD, Principal investigator, Erasmus Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05650918
- Sponsor's protocol ID
- NL76592.000.21
- Acronym
- REACtiVe-2
- Status last verified
- Oct 2023
- First submitted
- 8 Aug 2022
- Last updated
- 12 Oct 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dendritic Cells Loaded With Allogeneic Tumor Lysate (MesoPher) in Combination With a CD40 Agonist (Mitazalimab) in Metastatic Pancreatic Disease
- ClinicalTrials.gov ID
- NCT05650918
- Acronym / sponsor ID
- REACtiVe-2 / NL76592.000.21
- Conditions
- Metastatic Pancreatic Cancer
- Keywords
- Immunotherapy, CD40 agonist, Dendritic cell therapy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Joachim Aerts, MD PhDUniversity, hospital or other
- Study start
- 30 Aug 2021 (actual)
- Primary completion
- 23 May 2023 (actual)
- Study completion
- 23 May 2023 (actual)
- First posted
- 14 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.
Detailed description
Rationale: Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor. It is thought that the characteristic desmoplastic stroma of established pancreatic adenocarcinomas acts as a physical as well as an immunosuppressive barrier leading to exclusion of T cells. The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent and T-cell-independent mechanisms. Targeting the desmoplastic stroma, thereby making the tumor more permeable for T-cell infiltration, is seen as one of the assisting mechanisms. Furthermore, the immunological coldness of pancreatic cancers infers that tumor-reactive T-cell responses are absent or weak at best. Dendritic cell therapy introduces tumor-specific T cells and in combination with a CD40 agonist, may lead to synergistic anti-tumor responses which could be beneficial for pancreatic cancer patients.
Objective: To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic cancer after standard-of-care (SOC) treatment with (modified) FOLFIRINOX.
Study design: Open-label, single-center, phase I dose finding study using a modified toxicity probability interval (mTPI) design.
Study population: Adults with metastatic pancreatic cancer after SOC treatment with (modified) FOLFIRINOX.
Intervention: Leukapheresis is performed after which monocytes are used for differentiation to dendritic cells. Autologous dendritic cells pulsed with an allogeneic tumor lysate (MesoPher) will be administered intra-dermally and intravenously 3 times every 2 weeks. Booster vaccinations are given after 3 and 6 months. On the same day after administration of MesoPher a CD40 agonist (mitazalimab) will be administered intravenously.
Study parameters/endpoints: The main study endpoint are the dose-limiting toxicities of MesoPher/mitazalimab combination therapy. The secondary endpoints are the induced immune responses on therapy and the radiographical response rate according to RECIST and iRECIST.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients have to undergo additional outpatient clinic visits for this study and additional invasive procedures specifically for this trial, e.g. intravenous catheter placement and tumor metastasis biopsies. Although these are invasive procedures, associated risks are limited. Intravenous access is necessary during every visit, i.e. for leukapheresis, for drawing blood samples and for the administration of study medication. Leukapheresis is a standard procedure and will be performed according to our institutional guidelines. Leukapheresis demonstrates a limited risk for transient thrombocytopenia and leukopenia. Previous clinical studies have shown that injection with tumor lysate-pulsed dendritic cells (MesoPher) was well tolerated without major systemic toxicity, with the exception of low-grade flu-like symptoms (REACtiVE Trial, NL67169.000.18; DENIM/MM04: NCT03610360; MM03 NL44330.000.14 / NCT02395679).
Also, intravenous injection of mitazalimab up to 1200 µg/kg was well tolerated with manageable side effects. There are currently no trials investigating this combination therapy. Combining two immunomodulatory drugs increases the risk for toxicity. The objective of this phase I study is to investigate safety and tolerability of administrating MesoPher/mitazalimab combination therapy in metastatic pancreatic cancer patients. Patients may have potential beneficial anti-tumor responses following study medication.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- open-label, dose-finding, single-center phase I study
| Arm | Type | Receives |
|---|---|---|
| MesoPher and mitazalimab combination therapy | Experimental | Biological: MesoPher, Biological: MitazalimabMesoPher. 25 million lysate loaded DCs administered in the form of 3 biweekly and 2 additional vaccinations (3 and 6 months after the third vaccination). 1/3 intradermal injection in the forearm and 2/3 via the intravenous route. mitazalimab, 75µg/kg-150µg/kg-300µg/kg-600µg/kg or 1200µg/kg via intravenous route in the form of 3 biweekly and 2 additional infusions (3 and 6 months after the third vaccination). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Metastatic pancreatic cancer as defined by the presence of radiologically suspect metastatic lesions.
- Inclusion ≤ 4 weeks after stopping FOLFIRINOX chemotherapy.
- No more than 1 line of chemotherapy for metastatic disease is allowed. Prior FOLFIRINOX for locally advanced disease if given within 1 year before screening will be counted as first-line treatment. Any FOLFIRINOX given in the curative intent setting if more than a year before screening will not be considered first line therapy.
- An accessible metastatic lesion for histological tissue collection.
- Patients must be at least 18 years old and must be able to give written informed consent.
Key exclusion criteria (13 listed)
- Medical or psychological impediment to probable compliance with the protocol.
- Abdominal ascites.
- Current or previous use of a CD40 antibody and/or anti-tumor vaccinations.
- Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has undergone curative intent treatment and has been disease-free for two years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MesoPherautologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate) | Biological | MesoPher and mitazalimab combination therapy |
| Mitazalimabagonistic human monoclonal (IgG1) antibody targeting CD40 | Biological | MesoPher and mitazalimab combination therapy |
Primary outcome
Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0
Time frame: From first dose (week 0 of treatment phase) to end of the DLT observation period (week 6 of treatment phase)
The number of patients experiencing a DLT will be determined. Toxicities will be scored according to CTC criteria version 5.0 (Published November 27th, 2017). The toxicities occurring during 6 weeks after the first vaccination (i.e., the DLT observation period), will be considered as DLT, when considered possibly, probably or definitively related to MesoPher and/or mitazalimab combination therapy. All patients that cannot complete the first 3 doses as planned due to directly related toxicity will be discussed in the Study Steering Committee and they will determine whether the patient is classified as having a DLT.
5 secondary outcomes
Determine the presence of vaccine-induced dendritic cell mediated immune responses using ELISA and flow cytometry.
Time frame: From baseline to end of study (week 36)
Determine the intratumoral treatment effect by measuring T cell influx
Time frame: From baseline to week 6
Determine vaccine-induced changes in the frequency of immune cell subsets using flow cytometry
Time frame: From baseline to end of study (week 36)
Determining predictive gene expression signatures related to therapy outcome using NanoString technology
Time frame: From baseline to end of study (week 36)
Radiological response rate as defined by RECIST version 1.1 and iRECIST
Time frame: From baseline to end of study (week 36)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Oct 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Metastatic Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ferry Eskens, MD, PhD principal investigator
Erasmus Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing MesoPher and Mitazalimab in people with Metastatic Pancreatic Cancer, run by Joachim Aerts, MD PhD at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0 (time frame: From first dose (week 0 of treatment phase) to end of the DLT observation period (week 6 of treatment phase)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2023.